Digital Healthcare is fastest growing segment fueling the growth of Eye Flu (Conjunctivitis) Market

 Eye flu or Conjunctivitis is an inflammation or infection of the conjunctiva caused by bacterial or viral infections. Common symptoms include redness of the eyes, tearing, itching, and discharge from the eyes. Antibacterial and antiviral eye drops and ointments are commonly prescribed to reduce symptoms and speed up recovery.

The global Eye Flu (Conjunctivitis) Market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Digital healthcare platforms providing access to online consultations and e-prescriptions for eye flu treatment have seen increased adoption especially during the pandemic. Tele-ophthalmology allows patients to consult remotely with eye care specialists and obtain prompt diagnosis and prescriptions which has boosted the market. In addition, the availability of over-the-counter eye drops without a prescription for mild cases has increased convenience and accessibility of treatment.

Segment Analysis
Eye flu (conjunctivitis) can be broadly classified into three main segments - allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. Among these, allergic conjunctivitis accounts for the largest share as it is one of the most common types of eye allergy affecting people of all ages. It is caused due to airborne allergens such as pollen, dust, animal dander etc. resulting in redness, itching and watery discharge in the eyes.

Key Takeaways
The global eye flu (conjunctivitis) market is expected to witness high growth, exhibiting CAGR of 8.0% over the forecast period, due to increasing prevalence of allergic conjunctivitis worldwide.

Regional analysis
North America is currently the largest as well as the fastest growing regional market for eye flu treatment. This is majorly attributed to the high awareness regarding eye care and availability of advanced treatment options in the region. Asia Pacific is also expected to show lucrative growth in the coming years driven by vast population base, increasing healthcare expenditure and growing medical tourism in the region.

Key players
Key players operating in the eye flu (conjunctivitis) market are Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals, Akorn Pharmaceuticals, Alcon, Pfizer, Valeant Pharmaceuticals, Merck & Co., Similasan Corporation, Sun Pharmaceutical Industries, Prestige Consumer Healthcare, Lupin Pharmaceuticals, Alembic Pharmaceuticals, Aurolab, Intas Pharmaceuticals, Sun Pharma, Cipla.

Comments

Popular posts from this blog

Neuroendocrine Cancer is the fastest growing segment fueling the growth of Pituitary Cancer Market

Enhancing Patient Care and Comfort: The Evolution of Hospital Beds

Dry Eye Disease Market is Estimated to Witness High Growth Owing to Rising Awareness About Disease Management